MedTrace Logo

Treatment of Hematological Malignancy With Novel CAR-T Cells.

NCT04191941 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2019-12-10

No results posted yet for this study

Summary

This is a single arm, open-label, early phase I study, to determine the safety and efficacy of Novel CAR-T cell therapy in Hematological Malignancy treatment.

Conditions

Interventions

BIOLOGICAL

Novel CAR-T

A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of Novel CAR-T cells

Sponsors & Collaborators

  • Hunan Provincial People's Hospital

    collaborator OTHER

  • Timmune Biotech Inc.

    lead INDUSTRY

Principal Investigators

  • Ming Zhou · Hunan Provincial People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2021-08-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04191941 on ClinicalTrials.gov